@nephspace.bsky.socialWant to keep up with nephrology, but end up doomscrolling instead? 🎧
NephSpace makes the nutritious stuff as easy as the scroll: the week's kidney research and news in one place, as lively episodes for the couch, the run or the commute.
2-minute trailer: nephspace.com
@thelancetendo.bsky.social#Semaglutide was effective in decreasing #CKD progression regardless of the administration route or indication (type 2 #diabetes or #obesity), adding to the evidence provided by FLOW in people with type 2 diabetes & CKD www.thelancet.com/journals/lan...
#T2D
@thelancetendo.bsky.socialRead our October Issue, featuring type 1 diabetes, older adults, obesity, chronic kidney disease, type 2 diabetes, central precocious puberty, incretin therapies, endocrine-disrupting chemicals, climate change, & much more tinyurl.com/mwfu4c6m
